Application 204054
- Type
- ANDA
- Sponsor
- NEXGEN PHARMA
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | MECAMYLAMINE HYDROCHLORIDE | MECAMYLAMINE HYDROCHLORIDE | TABLET;ORAL | 2.5MG | No | Yes |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A204054-001 | MECAMYLAMINE HYDROCHLORIDE | MECAMYLAMINE HYDROCHLORIDE | 2.5MG | TABLET / ORAL | RS | 2013-03-19 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A204054-001 | MECAMYLAMINE HYDROCHLORIDE | 2.5MG | TABLET / ORAL | RS | 2013-03-19 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | A204054-001 | MECAMYLAMINE HYDROCHLORIDE | 2.5MG | TABLET / ORAL | RS | 2013-03-19 | f41ea6bd6efb… | |
| 2022-09-29 23:25 UTC | 2022-09 | A204054-001 | MECAMYLAMINE HYDROCHLORIDE | 2.5MG | TABLET / ORAL | RS | 2013-03-19 | e64feba35796… | |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A204054-001 | MECAMYLAMINE HYDROCHLORIDE | 2.5MG | TABLET / ORAL | RS | 2013-03-19 | cb3db0bc1861… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A204054-001 | MECAMYLAMINE HYDROCHLORIDE | 2.5MG | TABLET / ORAL | RS | 2013-03-19 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Vecamyl | MECAMYLAMINE HYDROCHLORIDE | TILDE Sciences LLC | 0b149023-f7a8-442d-ac69-295df8e66ed3 | 2025-02-20 | Warnings, Adverse reactions | 204054 ANDA204054 |
| Vecamyl | MECAMYLAMINE HYDROCHLORIDE | Vyera Pharmaceuticals, LLC | 0774cc48-7287-4093-91d6-9df41a81408a | 2022-11-09 | Warnings, Adverse reactions | 204054 ANDA204054 69413-558 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 0722-7183 | Mecamylamine Hydrochloride | Mecamylamine Hydrochloride | Nexgen Pharma, Inc. | ANDA | Current |
| 0722-7183 | Mecamylamine Hydrochloride | Mecamylamine Hydrochloride | Nexgen Pharma, Inc. | ANDA | Current |
| 45043-558 | Vecamyl | Mecamylamine Hydrochloride | Manchester Pharmaceuticals | ANDA | Current |
| 69413-558 | Vecamyl | Mecamylamine Hydrochloride | Vyera Pharmaceuticals, LLC | ANDA | Current |
| 69413-558 | Vecamyl | Mecamylamine Hydrochloride | Vyera Pharmaceuticals, LLC | ANDA | Current |
| 69413-558 | Vecamyl | Mecamylamine Hydrochloride | Vyera Pharmaceuticals, LLC | ANDA | Current |
| 79739-7183 | Mecamylamine Hydrochloride | Mecamylamine Hydrochloride | LGM Pharma Solutions, LLC | ANDA | Current |